The immuno-oncology market size was valued at US$45.12 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 20.30% during 2022-2030. The immuno-oncology market report provides an executive-level overview of the immuno-oncology market worldwide today, with detailed forecasts of key indicators up to 2030.
This market intelligence report offers a thorough, forward-looking analysis of the global immuno-oncology market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.
The immuno-oncology market size was valued at US$45.12 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of is expected to grow at a CAGR of more than 19% during the forecast period (2022-2030). Major factors such as an increase in healthcare expenditure, a rise in the prevalence and incidence of cancer, a surge in technological advancement in cancer treatment, and novel product launches are expected to boost market growth during the forecast period.
This market intelligence report offers a thorough, forward-looking analysis of the global immuno-oncology market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.
The immuno-oncology market size was valued at US$45.12 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of is expected to grow at a CAGR of more than 19% during the forecast period (2022-2030). Major factors such as an increase in healthcare expenditure, a rise in the prevalence and incidence of cancer, a surge in technological advancement in cancer treatment, and novel product launches are expected to boost market growth during the forecast period.
Scope
- Overview of immuno-oncology including classification of therapy and technologies, regulatory and market access details, and product & company profile
- Immuno-oncology market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the class, end-users, and geographic segments.
- Immuno-oncology market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the key class segments.
- Immuno-oncology market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the end-user segment.
- The competitive landscape: an examination of the positioning of leading players in the immune-oncology market.
Reasons to Buy
- This market intelligence report offers a thorough, forward-looking analysis of the global immuno-oncology market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.
- Accompanying the publisher's Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in immuno-oncology markets.
- The report also highlights key class and end-user segments.
- With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality.
- The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in immuno-oncology market.
Table of Contents
Chapter 1. Executive Summary
Chapter 2. Market Landscape
Chapter 3: Value Chain Analysis
Chapter 4: Porter’s Five Forces Analysis
Chapter 5: Regulatory Framework
Chapter 6: Immuno-oncology Market, Pipeline Analysis in 8MM
Chapter 8: Market Size 2022-2030
Chapter 9: Global Immuno-oncology Market by Class
Chapter 10: Global Immuno-oncology Market by End-User
Chapter 11: Global Immuno-oncology Market by Geography
Chapter 12: Trends, Drivers, and Challenges
Chapter 13: Companies
Chapter 14: Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- AstraZeneca Plc
- Palo Alto Networks Inc.
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Co.
- Johnson & Johnson Services Inc.
- LEGEND BIOTECH CORP.
- Gilead Sciences Inc.
- Merck & Co.
- Novartis AG
